Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung-Reference-Cited by-同舟云学术

Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung

Published:2012-09 Issue:5 Volume:8 Page:267-274
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Handorf Elizabeth A.¹,McElligott Sean¹,Vachani Anil¹,Langer Corey J.¹,Bristol Demeter Mirar¹,Armstrong Katrina¹,Asch David A.¹

Affiliation:

1. University of Pennsylvania Perelman School of Medicine; and VA Center for Health Equity Research and Promotion, Philadelphia, PA

Abstract

Cost-effectiveness analysis supports EGFR mutation testing in patients with stage IV or recurrent lung adenocarcinoma, rebiopsying if insufficient tissue is available, and first-line erlotinib treatment for those with EGFR mutations.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology(nursing),Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JOP.2011.000502

Reference33 articles.

1. Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

2. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

4. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

5. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-generation sequencing impact on cancer care: applications, challenges, and future directions;Frontiers in Genetics;2024-07-09

2. Issues Facing the Established Metastatic Bone Disease Patient: Timing/Indications for Surgery;Metastatic Bone Disease;2024

3. Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response;Cancers;2023-11-28

4. Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan;Clinical Drug Investigation;2023-10-27

5. Challenges and opportunities in building a health economic framework for personalized medicine in oncology;Personalized Medicine;2023-09